Kurt William Saionz

USPTO Granted Patents = 19 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 1)

Average Co-Inventor Count = 13.1

ph-index = 6

Forward Citations = 91(Granted Patents)

Company Filing History:

8 out of 2,405

Merck Sharp + Dohme Corp.

patents

8 out of 52

Pharmacopeia Drug Discovery, Inc.

Jacobus Pharmaceutical Company, Inc.

patents

6. 1 out of 188

Otsuka Pharmaceutical Factory, Inc.

patents

7. 1 out of 134

Ligand Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2016

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9409893 - Heteroaryl derivatives and uses thereof (2016-08-09),

2. 9062007 - Cyclic amide BACE-1 inhibitors having a benzamide substituent (2015-06-23),

3. 8937093 - Heterocyclic aspartyl protease inhibitors (2015-01-20),

4. 8895599 - Lipoprotein lipase-activating compositions comprising benzene derivates (2014-11-25),

5. 8829036 - Heterocyclic aspartyl protease inhibitors (2014-09-09),

6. 8822467 - Biaryl oxyacetic acid compounds (2014-09-02),

7. 8778980 - Heterocyclic aspartyl protease inhibitors (2014-07-15),

8. 8691833 - Heterocyclic aspartyl protease inhibitors (2014-04-08),

9. 8691831 - Heterocyclic aspartyl protease inhibitors (2014-04-08),

10. 8623867 - Cyclic amine BACE-1 inhibitors having a benzamide substituent (2014-01-07),

11. 8278334 - Cyclic amine BACE-1 inhibitors having a benzamide substituent (2012-10-02),

12. 8242112 - Heterocyclic aspartyl protease inhibitors (2012-08-14),

13. 8178513 - Heterocyclic aspartyl protease inhibitors (2012-05-15),

14. 7973067 - Heterocyclic aspartyl protease inhibitors (2011-07-05),

15. 7763609 - Heterocyclic aspartyl protease inhibitors (2010-07-27),

Title: The Innovative Contributions of Kurt William Saionz in Patent Development

Introduction: Kurt William Saionz, based in Cranford, NJ, has significantly impacted the field of pharmaceuticals through his inventive prowess. With a remarkable tally of 19 patents, Saionz has focused on developing novel compounds with practical applications in medicine, particularly in combating diseases such as malaria and Alzheimer’s.

Latest Patents: Among his most notable inventions is a patent for "Heteroaryl derivatives and uses thereof," targeting antimalarial compounds designed to fight drug-resistant strains of Plasmodia. This invention not only details the compounds but also outlines their compositions and the processes for their synthesis. Another significant patent by Saionz involves "Cyclic amide BACE-1 inhibitors having a benzamide substituent." This groundbreaking work includes pharmaceutical compositions that provide methods for treating cognitive and neurodegenerative diseases, including Alzheimer's. The patent emphasizes a cooperative approach that combines various therapeutic agents to enhance treatment efficacy.

Career Highlights: Kurt William Saionz's career includes noteworthy tenures at leading companies in pharmaceutical research and development. He has worked at Merck Sharp & Dohme Corporation, where he developed numerous essential medical compounds, and Pharmacopeia Drug Discovery, Inc., furthering his contributions to innovative drug discovery and development.

Collaborations: Throughout his career, Saionz has worked alongside accomplished colleagues, including Tao Guo and Andrew William Stamford. Their collective efforts have propelled advancements in their respective fields, nurturing a collaborative spirit that has fostered significant innovations in drug development.

Conclusion: Kurt William Saionz stands as a prominent figure in pharmaceutical innovation, having made invaluable contributions through his extensive patent portfolio. His work, focused on addressing critical health challenges, underscores the vital role of inventors in advancing medical science and improving health outcomes for society.

This text is generated by artificial intelligence and may not be accurate.